173 related articles for article (PubMed ID: 34228553)
1. Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization.
Ng DSC; Ho M; Iu LPL; Lai TYY
Expert Opin Drug Saf; 2022 Jan; 21(1):43-54. PubMed ID: 34228553
[TBL] [Abstract][Full Text] [Related]
2. Ranibizumab for myopic choroidal neovascularization.
Ng DSC; Fung NSK; Yip FLT; Lai TYY
Expert Opin Biol Ther; 2020 Dec; 20(12):1385-1393. PubMed ID: 33003962
[TBL] [Abstract][Full Text] [Related]
3. Pharmacotherapy of Myopic Choroidal Neovascularization.
Isildak H; Schwartz SG; Flynn HW
Curr Pharm Des; 2018; 24(41):4853-4859. PubMed ID: 30674251
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor inhibitor use and treatment approach for choroidal neovascularization secondary to pathologic myopia.
Pakzad-Vaezi K; Mehta H; Mammo Z; Tufail A
Expert Opin Biol Ther; 2016 Jul; 16(7):873-81. PubMed ID: 26985834
[TBL] [Abstract][Full Text] [Related]
5. Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization.
Sayanagi K; Uematsu S; Hara C; Wakabayashi T; Fukushima Y; Sato S; Ikuno Y; Nishida K
Graefes Arch Clin Exp Ophthalmol; 2019 Apr; 257(4):749-757. PubMed ID: 30643966
[TBL] [Abstract][Full Text] [Related]
6. Anti-VEGF treatment for myopic choroid neovascularization: from molecular characterization to update on clinical application.
Zhang Y; Han Q; Ru Y; Bo Q; Wei RH
Drug Des Devel Ther; 2015; 9():3413-21. PubMed ID: 26170626
[TBL] [Abstract][Full Text] [Related]
7. Anti-VEGF Therapy in Myopic CNV.
Toto L; Di Antonio L; Costantino O; Mastropasqua R
Curr Drug Targets; 2021; 22(9):1054-1063. PubMed ID: 33511955
[TBL] [Abstract][Full Text] [Related]
8. The role of anti-VEGF agents in myopic choroidal neovascularization: Current standards and future outlook.
Munk MR; Rückert R; Zinkernagel M; Ebneter A; Wolf S
Expert Opin Biol Ther; 2016; 16(4):477-87. PubMed ID: 26666589
[TBL] [Abstract][Full Text] [Related]
9. Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization.
Ahn SJ; Park KH; Woo SJ
Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5794-800. PubMed ID: 26325418
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization.
Lai TY; Luk FO; Lee GK; Lam DS
Eye (Lond); 2012 Jul; 26(7):1004-11. PubMed ID: 22595908
[TBL] [Abstract][Full Text] [Related]
11. Anti-vascular endothelial growth factor for myopic choroidal neovascularization.
Ng DS; Kwok AK; Chan CW
Clin Exp Ophthalmol; 2012; 40(1):e98-e110. PubMed ID: 21902785
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization.
Yoon JU; Byun YJ; Koh HJ
Retina; 2010 Mar; 30(3):418-24. PubMed ID: 20094012
[TBL] [Abstract][Full Text] [Related]
13. Anti-Vascular Endothelial Growth Factor Therapy for Myopic Choroidal Neovascularization.
Ng DSC; Lai TYY; Cheung CMG; Ohno-Matsui K
Asia Pac J Ophthalmol (Phila); 2017; 6(6):554-560. PubMed ID: 29057641
[TBL] [Abstract][Full Text] [Related]
14. CHOROIDAL THICKNESS AND CHORIORETINAL ATROPHY IN MYOPIC CHOROIDAL NEOVASCULARIZATION WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
Lee JH; Lee SC; Kim SH; Koh HJ; Kim SS; Byeon SH; Lee CS
Retina; 2017 Aug; 37(8):1516-1522. PubMed ID: 27798519
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal conbercept for choroidal neovascularisation secondary to pathological myopia in a real-world setting in China : Intravitreal conbercept was safe and effective in treating myopic choroidal neovascularization.
Nie X; Wang Y; Yi H; Qiao Y
BMC Ophthalmol; 2021 Mar; 21(1):116. PubMed ID: 33663431
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis.
Wang E; Chen Y
Retina; 2013; 33(7):1375-92. PubMed ID: 23514793
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab for choroidal neovascularization secondary to age-related macular degeneration and pathological myopia.
Hashemi S; Faramarzi MA; Ghasemi Falavarjani K; Abdollahi M
Expert Opin Biol Ther; 2014 Dec; 14(12):1837-48. PubMed ID: 25283631
[TBL] [Abstract][Full Text] [Related]
18. Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia.
Cohen SY
Retina; 2009 Sep; 29(8):1062-6. PubMed ID: 19734760
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study.
Ikuno Y; Ohno-Matsui K; Wong TY; Korobelnik JF; Vitti R; Li T; Stemper B; Asmus F; Zeitz O; Ishibashi T;
Ophthalmology; 2015 Jun; 122(6):1220-7. PubMed ID: 25745875
[TBL] [Abstract][Full Text] [Related]
20. Long-term effect of intravitreal injection of anti-VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularization.
Oishi A; Yamashiro K; Tsujikawa A; Ooto S; Tamura H; Nakata I; Miyake M; Yoshimura N
Graefes Arch Clin Exp Ophthalmol; 2013 Jan; 251(1):1-7. PubMed ID: 22527326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
